ArticleHepatology (Baltimore, Md.)2020
Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.
Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Optimizing Inpatient Phototherapy in Adult Crigler-Najjar Syndrome Type 1: A Practical Framework for Acute Hyperbilirubinemia Management.ACG case reports journal · 2026Article
- Liver Transplantation Outcomes in Crigler-Najjar Syndrome in Iran: A Single-Center Retrospective Cohort Study Over 20 Years.Health science reports · 2026Article
- Expert Consensus on the Diagnosis and Management of Inherited Hyperbilirubinemia (2025).Journal of clinical and translational hepatology · 2026Article
- [Expert consensus on the diagnosis and therapy of inherited hyperbilirubinemia (version 2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Clinical development of therapeutic mRNA applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Article
- Controversies in our understanding of extreme hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient neonates.Pediatric research · 2025Review
- The Multifaceted Role of Bilirubin in Liver Disease: A Literature Review.Journal of clinical and translational hepatology · 2024Review
- Therapeutic Options for Crigler-Najjar Syndrome: A Scoping Review.International journal of molecular sciences · 2024Article
- [Correlation between the mutation spectrum of the UGT1A1 gene and clinical phenotype in patients with inherited hyperunconjugated bilirubinemia].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Crigler-Najjar syndrome: looking to the future does not make us forget the present.Orphanet journal of rare diseases · 2024Article
- Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model.Molecular therapy. Methods & clinical development · 2023Article
- Nanomaterials for mRNA-based therapeutics: Challenges and opportunities.Bioengineering & translational medicine · 2023Review
- The added value of brain MR spectroscopy in children with Crigler-Najjar syndrome type-I: correlation with demographic, neurodevelopmental, and laboratory findings.The British journal of radiology · 2023Article
- Case report: Crigler-Najjar syndrome type 1 in Croatia-more than a one in a million: a case series.Frontiers in pediatrics · 2023Article
- Genetic alterations and molecular mechanisms underlying hereditary intrahepatic cholestasis.Frontiers in pharmacology · 2023Review
- Blue-Green (~480 nm) versus Blue (~460 nm) Light for Newborn Phototherapy-Safety Considerations.International journal of molecular sciences · 2022Review
- Gilbert or Crigler-Najjar syndrome? Neonatal severe unconjugated hyperbilirubinemia with P364L UGT1A1 homozygosity.Italian journal of pediatrics · 2022Article
- Living Related Liver Transplantation for Metabolic Liver Diseases in Children.Journal of pediatric gastroenterology and nutrition · 2021Article
- Prediction of Drug-Induced Hyperbilirubinemia by In Vitro Testing.Pharmaceutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsWe describe the pathophysiology, treatment, and outcome of Crigler-Najjar type 1 syndrome (CN1) in 28 UGT1A1 c.222C>A homozygotes followed for 520 aggregate patient-years. APPROACH AND
resultsUnbound ("free") bilirubin (B
conclusionSeven decades after its discovery, CN1 remains a morbid and potentially fatal disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.